People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Other Health Care, Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ICC Holdings, LLC | — | Other Health Care | Series C | $52.6M | $1.0B | 2018 |
| NFlection Therapeutics, Inc. | — | Biotechnology | Series B | $44.0M | $43.5M | 2016 |
| Phoenicis Therapeutics, Inc. | — | Pharmaceuticals | Series A | $23.8M | $38.6M | 2025 |
| PellePharm, Inc. | — | Biotechnology | Series A | $19.6M | $271.1M | 2015 |
| FlightPath Biosciences, Inc. | — | Biotechnology | Series A | $9.6M | $82.3M | 2023 |
| Myotherix, Inc. | — | Biotechnology | Series A | $9.4M | $286.7M | 2015 |
| FibRx Derm, Inc. | — | Biotechnology | Series A | $4.2M | $151.8M | 2019 |
| Reilly's Hemp, Inc. | — | Other | Seed | $2.8M | $41.8M | 2019 |
| Seylanmed Llc | — | Biotechnology | Seed | $1.2M | $51.9M | 2019 |
| RNADerm Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $750K | $41.4M | 2019 |
Mark De Souza at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark De Souza on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.